KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts)

被引：0
|
作者：
Metro, Giulio [1 ]
Duranti, Simona [1 ]
Chiari, Rita [1 ]
Bennati, Chiara [1 ]
Molica, Carmen [1 ]
Curra, Maria Francesca [1 ]
Scafati, Chiara [1 ]
Siggillino, Annamaria [1 ]
Flacco, Antonella [1 ]
Marcomigni, Luca [1 ]
Ludovini, Vienna [1 ]
Minotti, Vincenzo [1 ]
Crino, Lucio [1 ]
机构：
[1] Azienda Osped Perugia, Dept Med Oncol, Santa Maria della Misericordia Hosp, Perugia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18023
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Combination effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and individual chemotherapeutics in non-small cell lung cancer (NSCLC) cells with and without sensitizing-EGFR mutations
    Tsai, C.
    Chang, K.
    Chiu, C.
    Hsiao, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) RELATED INTERSTITIAL LUNG DISEASE IN TAIWANESE PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Chiang, Chi-Lu
    Tsai, Chun-Ming
    Lee, Yu-Chin
    Chiu, Chao-Hua
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S592 - S592
  • [3] Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis
    Lee, H. J.
    Jeong, G. H.
    Li, H.
    Kim, M. S.
    Kim, J. S.
    Park, S. J.
    Han, Y. J.
    Lee, K. H.
    Kronbichler, A.
    Hong, S. H.
    Ghayda, R. A.
    Luchini, C.
    Nottegar, A.
    Koyanagi, A.
    Smith, L.
    Jacob, L.
    Dragioti, E.
    Radua, J.
    Cargnin, S.
    Terrazzino, S.
    Thompson, T.
    Yon, D. K.
    Lee, S. W.
    Yang, J. M.
    Wasuwanich, P.
    Shin, J. I.
    Gamerith, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (20) : 6232 - 6244
  • [4] FIRST-LINE TREATMENT WITH CYTOTOXIC CHEMOTHERAPY VERSUS EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI) IN PATIENTS WITH EGFR WILD-TYPE ADVANCED LUNG ADENOCARCINOMA
    Chai, Chee Shee
    Liam, Chong-Kin
    RESPIROLOGY, 2015, 20 : 90 - 90
  • [5] The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)
    Usui, K.
    Yokoyama, T.
    Kisohara, A.
    Mori, Y.
    Takeda, Y.
    Ishida, H.
    Kusano, N.
    Kishi, K.
    Katsushima, U.
    Kuwako, T.
    Aono, H.
    Shikama, Y.
    Minato, K.
    Matsushima, H.
    Uemura, K.
    Ohashi, Y.
    Kunitoh, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 514 - 514
  • [6] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
    Lee, Sanghun
    Joo, Jeonghyun
    Kwak, Minah
    Sohn, Kicheul
    Chon, Songha
    ONCOTARGETS AND THERAPY, 2018, 11 : 3943 - 3947
  • [8] Smoking history, drug toxicity, and survival in non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) drugs
    Cooley, M. E.
    Emmons, K. M.
    Li, H.
    Harrington, D. P.
    Christiani, D. C.
    Jackman, D. M.
    Cohen, T.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
    Mathy, A.
    Nederlof, P.
    Boerrigter, L.
    Van 't Veer, L.
    De Jong, D.
    Baas, P.
    Burgers, S.
    Van Zandwijk, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
  • [10] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345